Trial
NCT01639456
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
Miltenyi Biomedicine GmbH
Condition
Acute Myelogenous Leukemia
Intervention
CD3-/CD19- natural killer cells
Why stopped
study was abandoned and a new study was written to replace this one
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-02